Taking an NSAID like ibuprofen or naproxen while on Eliquis (apixaban) raises your risk of bleeding, and most clinical evidence points to the increase being meaningful enough to avoid the combination when possible. The two drugs attack different parts of the clotting process, and the overlap creates a compounding vulnerability. That said, the real-world picture is more layered than a blanket “never take them together,” and the choices you and your doctor make about which pain reliever, what dose, and how long can shift the risk considerably.
Why the Combination Increases Bleeding Risk
Eliquis works by blocking factor Xa, a protein near the end of the clotting cascade that is essential for forming stable blood clots. NSAIDs, meanwhile, inhibit an enzyme called cyclooxygenase (COX), which among other things helps platelets stick together. Each drug weakens a different arm of the clotting system. Put both together and you get an additive effect: the blood is both slower to form a clot through the coagulation cascade and less able to plug a wound through platelet aggregation. The result is that a small cut, an ulcer in the stomach lining, or a vessel weakened by high blood pressure has a harder time sealing itself off.
NSAIDs also carry their own direct threat to the gut. They irritate the stomach and upper intestinal lining and can cause peptic ulcers and small-bowel damage even in people not on blood thinners. Co-prescribing a proton pump inhibitor reduces the risk of ulcers and related complications, but the mucosal irritation makes the GI tract a particularly vulnerable site when anticoagulants are onboard too.
What the Large Clinical Trials Found
The most detailed look at this interaction comes from the ARISTOTLE trial, a large study that compared apixaban to warfarin in patients with atrial fibrillation. A secondary analysis of that trial tracked patients who started an NSAID after enrollment. Those who began NSAID use during follow-up had roughly 60 percent higher rates of major bleeding and 70 percent higher rates of clinically relevant nonmajor bleeding compared with patients who stayed off NSAIDs. Interestingly, the increase was not concentrated in gastrointestinal bleeding specifically; it appeared across multiple bleeding sites.1Circulation. Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial The analysis also found no significant interaction between NSAID use and the randomized treatment arm, meaning the added bleeding risk was similar whether the patient was on apixaban or warfarin.
Real-world data reinforce the signal. A large matched-cohort study of nearly 6,000 patients found that those combining an anticoagulant with an NSAID had about 66 percent higher odds of gastrointestinal bleeding than those on anticoagulant therapy alone.2PubMed Central. Real-World Bleeding Risk of Anticoagulant and Nonsteroidal Anti-inflammatory Drugs Combotherapy versus Anticoagulant Monotherapy And a Danish registry analysis focusing on atrial fibrillation patients on oral anticoagulants found that NSAID use was associated with not just more bleeding but also a 50 percent higher rate of stroke or systemic embolism, a finding that surprised many clinicians.3PubMed. Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation
One Study That Did Not Find Extra Risk
Not every analysis reaches the same conclusion. A recent study comparing bleeding outcomes in patients on oral anticoagulants with and without concurrent NSAIDs found that overall bleeding rates were essentially the same between the two groups, with no statistically significant difference in major or nonmajor bleeding events.4The American Journal of Medicine. Concomitant Oral Anticoagulants and Nonsteroidal Anti-inflammatory Drugs in Patients with Venous Thromboembolism and Atrial Fibrillation Thrombotic outcomes and mortality were also similar. This result is at odds with the ARISTOTLE analysis and the matched-cohort data described above.
How to reconcile the discrepancy? Study design matters here. The populations differed: some analyses captured patients with brief or occasional NSAID use, others looked at longer-term exposure, and the mix of NSAID types varied. Additionally, in some study populations, patients at highest bleeding risk may have been steered away from NSAIDs in the first place, which would dilute the apparent risk of the combination. The weight of evidence from larger, better-controlled analyses still tilts toward real added risk, but this divergent result is a reminder that the hazard is not uniform for everyone.
Does the Type of NSAID Matter?
It does, and this distinction is clinically useful. Traditional NSAIDs like ibuprofen, naproxen, and diclofenac inhibit both forms of the COX enzyme, COX-1 and COX-2. COX-1 is the form most responsible for maintaining the stomach lining and supporting platelet function, so blocking it is what drives much of the GI and bleeding risk. COX-2-selective NSAIDs (celecoxib being the best known) spare COX-1 at therapeutic doses and primarily block the form of the enzyme involved in inflammation and pain.
A multinational study drawing on databases from the UK and Quebec compared GI bleeding rates in atrial fibrillation patients taking direct oral anticoagulants alongside either COX-2-selective or non-selective NSAIDs. Patients on COX-2-selective drugs had roughly 37 percent lower rates of GI bleeding compared to those on traditional NSAIDs.5JAMA Network Open. Direct Oral Anticoagulants, COX-2–Selective NSAIDs, and Gastrointestinal Bleeding in Atrial Fibrillation That is a substantial difference and helps explain why some guidelines consider celecoxib a more acceptable option when an NSAID truly cannot be avoided in an anticoagulated patient.
A separate study looking at NSAID users on rivaroxaban or apixaban found no clinically significant difference when results were broken down by NSAID selectivity, though this analysis was smaller and may have lacked the statistical power to detect a difference.6PubMed Central. Impact of NSAID Use on Bleeding Rates for Patients Taking Rivaroxaban or Apixaban On balance, COX-2-selective NSAIDs appear to carry less GI bleeding risk in this context, though they do not eliminate it entirely.
The Stroke Signal That Surprised Researchers
Most of the conversation about NSAIDs and Eliquis centers on bleeding. Less discussed is the finding from the Danish registry study that NSAID use was linked to a higher rate of stroke or systemic embolism in patients already on oral anticoagulants. That analysis found a 50 percent elevated risk of these events among NSAID users, while heart attack rates were not significantly different.7PubMed. Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation
The mechanism behind this is not fully settled. One hypothesis is that NSAIDs can raise blood pressure and promote fluid retention, both of which increase cardiovascular strain and could destabilize existing atrial fibrillation. Another possibility is that NSAID-related GI bleeds, even minor ones, trigger temporary interruptions in anticoagulant therapy that leave patients vulnerable. Whatever the cause, the stroke finding adds another dimension to the risk conversation: it is not just about bleeding, but possibly about undercutting the very protection Eliquis is prescribed to provide.
Can a Proton Pump Inhibitor Offset the Danger?
Proton pump inhibitors (PPIs) like omeprazole, pantoprazole, and lansoprazole reduce stomach acid production and help protect the upper GI lining. For patients on direct oral anticoagulants, adding a PPI was associated with about a 25 percent reduction in the risk of severe upper GI bleeding, according to a study of patients treated with these newer anticoagulants for atrial fibrillation.8Heart. Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds The benefit was most pronounced in patients at highest baseline risk: older adults, those with elevated bleeding-risk scores, and those also on antiplatelet therapy.
Additional research has confirmed that combining a PPI with apixaban specifically appears to lower both GI bleeding and mortality compared with apixaban alone in high-risk patients.9PubMed Central. Association between proton pump inhibitors and anti-coagulants for a better prevention of gastrointestinal bleeding This is encouraging, but there are a few things worth knowing. PPIs primarily protect the stomach and upper intestine; they do not help with bleeding from the lower GI tract, which is another common site for anticoagulant-related bleeds. And PPIs have their own long-term concerns, including effects on calcium absorption and kidney function. For a patient who genuinely needs both Eliquis and an NSAID for a limited period, adding a PPI is a reasonable safeguard, but it is not a get-out-of-jail-free card.
How Many People on Eliquis Are Actually Taking NSAIDs?
More than you might expect, and often without their doctor’s full awareness. A survey of nearly 800 patients taking apixaban found that about a third were taking at least one over-the-counter product with a potentially serious interaction on a daily or near-daily basis. Ibuprofen and naproxen were taken daily by a small minority (under 2 percent), but occasional use was far more common, with nearly 30 percent of respondents reporting they used these drugs some days or as needed.10Journal of the American Geriatrics Society. Prevalence and Knowledge of Potential Interactions Between Over‐the‐Counter Products and Apixaban Aspirin was another frequent co-user: about 15 percent of respondents took it daily, and nearly two-thirds of those daily aspirin users were also consuming other potentially interacting OTC products.
These numbers matter because the OTC nature of ibuprofen and naproxen means purchases do not pass through a pharmacist screening step in the same way a prescription does. Patients may not mention them to their cardiologist because they think of them as harmless painkillers rather than medications that interact with their blood thinner. A separate pharmacy-based survey found that while half of all anticoagulant patients had recently purchased over-the-counter analgesics, the purchase of ibuprofen and aspirin specifically was rare at about 6 percent.11Basic & Clinical Pharmacology & Toxicology. Switching, Adverse Effects and Use of Over‐the‐Counter Analgesics among Users of Oral Anticoagulants: A Pharmacy‐based Survey The discrepancy between these two surveys likely reflects differences in how and where the data were collected, but both confirm that the issue is not hypothetical.
What to Use for Pain Instead
The most common substitute when a pharmacist flags an NSAID-anticoagulant interaction is acetaminophen (paracetamol). In a prospective study of over 780 such interaction cases identified by community pharmacists, pharmacist-physician discussions led to a medication change about 40 percent of the time, and the most frequent switch was replacing the NSAID with acetaminophen.12British Journal of Clinical Pharmacology. Prevalence and management of drug interactions between nonsteroidal anti‐inflammatory drugs and antithrombotics in ambulatory care In the remaining 60 percent of cases, physicians opted to keep the NSAID, most often because the intended use was short-term.
Acetaminophen does not carry the platelet or GI risks of NSAIDs, which makes it a safer companion for Eliquis. Its limitation is that it works differently: it relieves pain and reduces fever but does relatively little for inflammation. For conditions where inflammation is the core driver of symptoms, like an arthritic flare or a sports injury, acetaminophen may not cut it.
Other options your doctor might consider include:
- Topical NSAIDs: Gels and creams containing diclofenac deliver the drug directly to the affected joint or muscle with much less entering the bloodstream. Systemic levels are far lower than with oral NSAIDs, which reduces the additive bleeding concern. These work best for localized pain, not widespread conditions.
- Celecoxib at the lowest effective dose: As discussed above, COX-2-selective NSAIDs appear to carry a lower GI bleeding risk. Some physicians will prescribe a short course of celecoxib for a patient on Eliquis when the pain cannot be managed otherwise, sometimes alongside a PPI.
- Non-drug approaches: Physical therapy, ice and heat, bracing, and corticosteroid injections directly into a joint can manage many musculoskeletal pain episodes without systemic medication.
The right call depends on how severe the pain is, how long you need relief, and what your overall bleeding risk profile looks like. A single dose of ibuprofen for a bad headache is a very different proposition from daily naproxen for chronic back pain.
Does Eliquis at Least Do Better Than Warfarin Here?
If you are going to be on a blood thinner and you might occasionally need an NSAID, you might wonder whether Eliquis offers any advantage over the older anticoagulant warfarin in terms of handling that overlap. A polypharmacy analysis from the ARISTOTLE trial found that apixaban maintained its advantage over warfarin in preventing stroke regardless of how many other medications patients were taking. For bleeding, the story was a bit more nuanced: apixaban’s relative safety advantage over warfarin narrowed somewhat as the total number of concomitant drugs increased, but it was still present across all groups, including those on the most medications.13BMJ. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial This does not mean that adding an NSAID to apixaban is safe, but it does suggest that if you are already on a newer anticoagulant, you are starting from a somewhat better baseline than you would be on warfarin.
What Happens If a Major Bleed Occurs
One of the historical concerns with newer anticoagulants like Eliquis was the lack of a reversal agent. That has been addressed. Andexanet alfa is a specific reversal drug approved for patients on factor Xa inhibitors (apixaban and rivaroxaban) who experience life-threatening or uncontrolled bleeding. It works rapidly, reducing anti-factor Xa activity within about two minutes of an intravenous bolus, and its effect is maintained during a two-hour infusion that follows.14European Heart Journal Supplements. Management of bleeding in patients on direct oral anticoagulants in emergency department: where we are and where we are going If andexanet alfa is not available, emergency physicians can use prothrombin complex concentrate as an alternative, though andexanet alfa is preferred when accessible.
Knowing a reversal agent exists is reassuring, but it is an emergency intervention, not a safety net that makes the NSAID combination less risky in daily life. The overwhelming majority of excess bleeds from this drug interaction are managed by stopping the medications, applying supportive care, and waiting. The reversal agent is reserved for the rare catastrophic event. Prevention, by avoiding or minimizing NSAID exposure, is the far better strategy.
When Short-Term NSAID Use Gets a Pass
In the pharmacist intervention study mentioned earlier, physicians who chose to keep the NSAID most often justified the decision by saying it was intended for short-term use only.15British Journal of Clinical Pharmacology. Prevalence and management of drug interactions between nonsteroidal anti‐inflammatory drugs and antithrombotics in ambulatory care This reflects a practical reality: a three-day course of ibuprofen for a dental procedure or a brief round of naproxen after a minor injury exposes you to far less cumulative risk than weeks or months of daily use. The ARISTOTLE trial’s bleeding signal emerged in patients who became ongoing NSAID users during follow-up, and the hazard in the real-world matched-cohort study also reflected sustained co-therapy rather than isolated doses.
That does not mean a single dose is risk-free, but the conversation your doctor has with you should be different for “I need something for a headache this afternoon” versus “I want to manage my knee arthritis with naproxen every day.” For the former, many physicians will cautiously agree to a low dose for a day or two. For the latter, the alternatives outlined above become much more important.
If you do end up needing a short NSAID course while on Eliquis, the general advice is to use the lowest effective dose for the shortest possible duration, choose a COX-2-selective option if available and appropriate, consider adding a PPI for stomach protection, and watch for signs of bleeding such as black or tarry stools, unexplained bruising, blood in the urine, or unusual fatigue. Let your prescriber know so they can adjust monitoring if needed.